Cargando…
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
PURPOSE: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250456/ https://www.ncbi.nlm.nih.gov/pubmed/35298693 http://dx.doi.org/10.1007/s00259-022-05756-2 |
_version_ | 1784739816206761984 |
---|---|
author | Roberts, Matthew J. Morton, Andrew Papa, Nathan Franklin, Anthony Raveenthiran, Sheliyan Yaxley, William J. Coughlin, Geoffrey Gianduzzo, Troy Kua, Boon McEwan, Louise Wong, David Delahunt, Brett Egevad, Lars Samaratunga, Hemamali Brown, Nicholas Parkinson, Robert Emmett, Louise Yaxley, John W. |
author_facet | Roberts, Matthew J. Morton, Andrew Papa, Nathan Franklin, Anthony Raveenthiran, Sheliyan Yaxley, William J. Coughlin, Geoffrey Gianduzzo, Troy Kua, Boon McEwan, Louise Wong, David Delahunt, Brett Egevad, Lars Samaratunga, Hemamali Brown, Nicholas Parkinson, Robert Emmett, Louise Yaxley, John W. |
author_sort | Roberts, Matthew J. |
collection | PubMed |
description | PURPOSE: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy. METHODS: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and (68) Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis. RESULTS: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters. CONCLUSION: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05756-2. |
format | Online Article Text |
id | pubmed-9250456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-92504562022-07-04 Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy Roberts, Matthew J. Morton, Andrew Papa, Nathan Franklin, Anthony Raveenthiran, Sheliyan Yaxley, William J. Coughlin, Geoffrey Gianduzzo, Troy Kua, Boon McEwan, Louise Wong, David Delahunt, Brett Egevad, Lars Samaratunga, Hemamali Brown, Nicholas Parkinson, Robert Emmett, Louise Yaxley, John W. Eur J Nucl Med Mol Imaging Short Communication PURPOSE: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy. METHODS: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and (68) Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis. RESULTS: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters. CONCLUSION: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05756-2. Springer Berlin Heidelberg 2022-03-17 2022 /pmc/articles/PMC9250456/ /pubmed/35298693 http://dx.doi.org/10.1007/s00259-022-05756-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Short Communication Roberts, Matthew J. Morton, Andrew Papa, Nathan Franklin, Anthony Raveenthiran, Sheliyan Yaxley, William J. Coughlin, Geoffrey Gianduzzo, Troy Kua, Boon McEwan, Louise Wong, David Delahunt, Brett Egevad, Lars Samaratunga, Hemamali Brown, Nicholas Parkinson, Robert Emmett, Louise Yaxley, John W. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
title | Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
title_full | Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
title_fullStr | Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
title_full_unstemmed | Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
title_short | Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
title_sort | primary tumour psma intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250456/ https://www.ncbi.nlm.nih.gov/pubmed/35298693 http://dx.doi.org/10.1007/s00259-022-05756-2 |
work_keys_str_mv | AT robertsmatthewj primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT mortonandrew primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT papanathan primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT franklinanthony primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT raveenthiransheliyan primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT yaxleywilliamj primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT coughlingeoffrey primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT gianduzzotroy primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT kuaboon primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT mcewanlouise primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT wongdavid primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT delahuntbrett primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT egevadlars primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT samaratungahemamali primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT brownnicholas primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT parkinsonrobert primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT emmettlouise primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy AT yaxleyjohnw primarytumourpsmaintensityisanindependentprognosticbiomarkerforbiochemicalrecurrencefreesurvivalfollowingradicalprostatectomy |